NCT01445080 2021-02-02Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaNational Cancer Institute (NCI)Phase 1/2 Completed70 enrolled 26 charts
NCT00217646 2015-04-28Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNational Cancer Institute (NCI)Phase 1 Completed36 enrolled
NCT00131989 2013-01-09Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaNational Cancer Institute (NCI)Phase 1 Completed48 enrolled
NCT00118170 2013-01-07Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNational Cancer Institute (NCI)Phase 1 Completed150 enrolled